Phase 2 Study Shows Opdivo-Yervoy Highly Effective In Colon CancerBy Press Room7 June 2024 A four-week course of dual immunotherapy prior to surgery is highly effective in treating a certain type of non-metastatic colorectal…
Why Is The FDA Concerned About Secondary Cancers After CAR T Cells?By Press Room13 March 2024 In November, the FDA released an announcement saying it was investigating reports of secondary cancers in people with blood cancers…
FDA Approves New Cellular Immunotherapy For Skin CancerBy Press Room21 February 2024 The FDA has granted accelerated approval to a new type of cellular therapy for use in people who have skin…